Fintel reports that on April 19, 2023, Needham reiterated coverage of Annexon (NASDAQ:ANNX) with a Buy recommendation.
Analyst Price Forecast Suggests 256.57% Upside
As of April 6, 2023, the average one-year price target for Annexon is $18.51. The forecasts range from a low of $8.08 to a high of $31.50. The average price target represents an increase of 256.57% from its latest reported closing price of $5.19.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Annexon is $0MM. The projected annual non-GAAP EPS is -$2.23.
What are Other Shareholders Doing?
Federated Hermes holds 3,058K shares representing 6.06% ownership of the company. No change in the last quarter.
Barclays holds 33K shares representing 0.07% ownership of the company. In it's prior filing, the firm reported owning 8K shares, representing an increase of 74.95%. The firm decreased its portfolio allocation in ANNX by 99.86% over the last quarter.
UBS Group holds 4K shares representing 0.01% ownership of the company. In it's prior filing, the firm reported owning 3K shares, representing an increase of 29.51%. The firm increased its portfolio allocation in ANNX by 0.29% over the last quarter.
CSCVX - CornerCap Small-Cap Value Fund Advisor Class holds 22K shares representing 0.04% ownership of the company.
FSMAX - Fidelity Extended Market Index Fund holds 197K shares representing 0.39% ownership of the company. In it's prior filing, the firm reported owning 139K shares, representing an increase of 29.40%. The firm increased its portfolio allocation in ANNX by 31.54% over the last quarter.
What is the Fund Sentiment?
There are 139 funds or institutions reporting positions in Annexon. This is a decrease of 4 owner(s) or 2.80% in the last quarter. Average portfolio weight of all funds dedicated to ANNX is 0.30%, an increase of 1.67%. Total shares owned by institutions increased in the last three months by 2.28% to 53,353K shares. The put/call ratio of ANNX is 0.34, indicating a bullish outlook.
Annexon Background Information
(This description is provided by the company.)
Annexon, Inc., doing business as Annexon Biosciences, operates as a clinical-stage biopharmaceutical company. The Company develops novel therapies for auto-immune and neurodegenerative diseases of body, eye, and brain. Annexon Biosciences serves patients in the State of California.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.